摘要
目的 分析2015—2020年黄山市疑似预防接种异常反应(adverse events following immunization,AEFI)的特征。方法 通过中国AEFI监测信息系统收集2015—2020年黄山市AEFI个案数据,采用描述流行病学方法进行分析。结果 2015—2020年黄山市共报告AEFI 727例,报告发生率为34.44/10万,其中严重AEFI 7例,报告发生率为0.33/10万。一般反应、异常反应分别占89.00%和10.45%,报告发生率分别为30.65/10万和3.60/10万,一般反应以发热、红肿、硬结为主,异常反应以过敏性皮疹和荨麻疹为主;县报告发生率(38.45/10万)高于城区(28.93/10万),差异有统计学意义(χ^(2)=13.534,P<0.01)。结论 2015—2020年黄山市AEFI发生率在预期范围内,以一般反应为主,严重反应罕见,应重点加强城区AEFI监测。
Objective To analyze the characteristics of adverse events following immunization(AEFI)in Huangshan City from 2015 to 2020.Methods The case data of AEFI in Huangshan City from 2015 to 2020 were collected through the China AEFI monitoring information system,and the descriptive epidemiological methods was used for analysis.Results A total of 727 cases of AEFI were reported in Huangshan City from 2015 to 2020,with a reported incidence of 34.44/100000,including 7 cases of severe AEFI,with a reported incidence of 0.33/100000.The general reactions and abnormal reactions accounted for 89.00%and 10.45%respectively,and the reported incidence rates were 30.65/100000 and 3.60/100000,respectively.The general reactions were mainly fever,swelling and induration,while the abnormal reactions were mainly allergic rash and urticaria.The reported incidence in counties(38.45/100000)was higher than that in urban areas(28.93/100000),and the difference was statistically significant(χ^(2)=13.534,P<0.01).Conclusions The incidence of AEFI in Huangshan City from 2015 to 2020 is within the expected range,mainly general reactions,and rare serious reactions.We should focus on strengthening the monitoring of AEFI in urban areas.
作者
张向阳
史四九
方杰敏
何江琴
ZHANG Xiangyang;SHI Sijiu;FANG Jiemin;HE Jiangqin(Department of Immunization and Tuberculosis Control,Huangshan Center for Disease Control and Prevention,Huangshan Anhui,245000,China;BCG Department,Anhui Institute of Tuberculosis Control and Prevention,Hefei Anhui,230022,China)
出处
《职业与健康》
CAS
2024年第2期215-219,共5页
Occupation and Health
关键词
疑似预防接种异常反应
监测
疫苗
Adverse events following immunization
Monitoring
Vaccine